Novadaq Technologies Inc.

Novadaq Technologies Inc.

December 05, 2006 08:00 ET

Novadaq to Present at BMO Capital Markets Focus on Healthcare Conference

TORONTO, ONTARIO--(Marketwire - Dec. 5, 2006) -

Attention Business Editors:

Novadaq® Technologies Inc. (TSX:NDQ), a developer of medical imaging
systems for the operating room, today announced that Dr. Arun Menawat,
President and Chief Executive Officer, will present the corporate story,
technology and highlights, including an update on clinical and commercial
development for both the OPTTX® System and LUNA™, at the BMO Capital
Markets Focus on Healthcare Conference. The conference takes place on
Wednesday, December 6 and Thursday, December 7 at the Millenium Broadway
Hotel, New York City. Dr. Menawat presents at 4:30 pm on Wednesday,
December 6 and his presentation will be webcast on Novadaq's website.

About Novadaq Technologies

Novadaq Technologies Inc. (TSX:NDQ) develops and commercializes medical
devices based on its proprietary imaging platform for the diagnosis and
treatment of human vascular and ophthalmic diseases and conditions. Novadaq's
SPY® Intra-operative Imaging System, commercially available worldwide,
enables cardiac surgeons to visually assess coronary vasculature and bypass
graft functionality during the course of open-heart surgery. Novadaq's
ophthalmic product, the OPTTX System, is aimed at the diagnosis, evaluation
and treatment of wet Age-related Macular Degeneration (AMD) by using the same
core imaging technology that is used in the SPY System. Novadaq received CE
Mark approval for the OPTTX System in November 2006 and expects a limited
launch in Europe by year end. Novadaq's product for urology, LUNA is designed
to enable surgeons to visualize nerve bundles during the course of urological
procedures such as radical prostatectomy in order to reduce negative outcomes
including impotency. For more information, please visit the company's website

Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by such statements,
and therefore these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on Novadaq's
current beliefs as well as assumptions made by and information currently
available to Novadaq and relate to, among other things, anticipated financial
performance, business prospects, strategies, regulatory developments,
commercial launch dates, market acceptance and future commitments. Readers are
cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date of this press release. Due to risks and
uncertainties, including the risks and uncertainties identified by Novadaq in
its public securities filings; actual events may differ materially from
current expectations. Novadaq disclaims any intention or obligation to update
or revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by law.

For further information: visit our website at

Contact Information